CGRP vs Oxytocin

Binds CLR/RAMP1 receptor complex. Causes vasodilation via cAMP/PKA/nitric oxide pathway. Modulates nociceptive signaling in the trigeminal system. Promotes bone healing and has anti-inflammatory effects in peripheral tissues.

CGRP (calcitonin gene-related peptide) is a 37-amino-acid endogenous neuropeptide produced by alternative splicing of the calcitonin gene, expressed predominantly in sensory neurons of the trigeminal system and peripheral vasculature, where it functions as a potent vasodilator and pain neuromodulator central to migraine pathophysiology. CGRP activates its receptor complex (CLR/RAMP1) to mediate vasodilation and nociceptive signal amplification; during migraine attacks, trigeminal activation releases CGRP at elevated plasma concentrations, and blockade of this pathway has been established as the primary validated pharmacological target for modern preventive migraine therapy. Phase 3 randomized controlled trials published in the New England Journal of Medicine and the Lancet — including the STRIVE trial (Goadsby et al. 2017) and a Phase 3b study in treatment-refractory patients — demonstrated that anti-CGRP monoclonal antibodies significantly reduced monthly migraine days versus placebo, validating the pathway and supporting FDA approval of erenumab, fremanezumab, and galcanezumab. CGRP itself is an endogenous neuropeptide and is not a therapeutic agent that is compounded or administered by providers; the FDA-approved interventions are monoclonal antibody and small-molecule receptor antagonists available by prescription, and exogenous CGRP peptide is exclusively a research tool compound used in vasodilatory and pain signaling pharmacology studies.

Neuropeptide hormone binding oxytocin receptors throughout brain and body; modulates HPA axis, reduces cortisol, promotes parasympathetic tone

Oxytocin is an endogenous hypothalamic nonapeptide and FDA-approved prescription medication (Pitocin) indicated for initiation and augmentation of labor, management of postpartum uterine atony and hemorrhage, and stimulation of milk letdown in breastfeeding women, acting through peripheral oxytocin receptors in the uterus and mammary gland. Beyond its obstetric and lactation roles, oxytocin functions centrally as a neuromodulator in limbic and cortical circuits involved in social recognition, attachment, trust behavior, and fear regulation, with broadly distributed brain oxytocin receptors mediating effects distinct from its peripheral reproductive actions. A landmark randomized, double-blind trial published in Nature demonstrated that intranasal oxytocin significantly increases trust in humans, and controlled research has subsequently characterized its effects on social attention to facial cues and affective empathy, establishing the central prosocial pharmacology of the peptide in human subjects. Oxytocin is FDA-approved only for its obstetric and lactation indications; intranasal formulations for prosocial, cognitive, or psychiatric applications are investigational, and while the mechanistic rationale is established in healthy-volunteer research, no intranasal oxytocin product has received regulatory approval for any psychiatric or behavioral indication. Intranasal oxytocin in research: studies have administered intranasal oxytocin in doses of 20–40 IU, with 24 IU being the most commonly used dose in human behavioral pharmacology research. This delivery route is studied for the hypothesis that olfactory epithelium absorption provides partial access to the CNS beyond what the blood-brain barrier would permit from systemic routes. Research applications under active investigation include autism spectrum disorder (multiple RCTs examining social cognition outcomes), PTSD (fear extinction augmentation), social anxiety disorder, and borderline personality disorder — none of which has produced a regulatory-ready efficacy signal sufficient for approval as of 2025, though ongoing trial activity is substantial. Oxytocin's anti-inflammatory research profile is also documented — oxytocin receptors are expressed on immune cells and the peptide has been shown to suppress pro-inflammatory cytokine release in preclinical models, an emerging research direction that intersects with gut and systemic inflammation contexts. Telehealth providers and compounding pharmacies offering oxytocin formulations for clinical contexts are listed in the PeptideBase directory.